Ondansetron interactions
Full monograph for OndansetronCheck it against another medicine
Medicines
671 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Almotriptan | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Amiodarone Hydrochloride | Major | Synergy | Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related… | 45 sources — open the full entry |
| Amisulpride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Amitriptyline Hydrochloride | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as antidepressants and lithium may potentiate the… | 7 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as antidepressants and lithium may potentiate the… | 7 sources — open the full entry |
| Arsenic Trioxide | Major | Synergy | Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the… | 4 sources — open the full entry |
| Artemether + Lumefantrine | Major | Synergy | Artemether-lumefantrine may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…2 documented mechanisms | 16 sources — open the full entry |
| Bupropion Hydrochloride | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Cabozantinib | Major | Synergy | Cabozantinib can cause prolongation of the QT interval. | 7 sources — open the full entry |
| Ceritinib | Major | Synergy | Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval… | 9 sources — open the full entry |
| Chloroquine Phosphate | Major | Synergy | Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong… | 22 sources — open the full entry |
| Citalopram Hydrobromide | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs)… | 16 sources — open the full entry |
| Clomipramine Hydrochloride | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as antidepressants and lithium may potentiate the… | 7 sources — open the full entry |
| Clozapine | Major | Synergy | Clozapine has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can cause QT prolongation… | 13 sources — open the full entry |
| Crizotinib | Major | Synergy | Crizotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT… | 6 sources — open the full entry |
| Desvenlafaxine Succinate | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Dextromethorphan + Bupropion | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors…2 documented mechanisms | 7 sources — open the full entry |
| Dextromethorphan + Phenylephrine + Triprolidine | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Dextromethorphan + Pseudoephedrine + Triprolidine | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Dextromethorphan Hydrobromide | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Dextromethorphan Hydrobromide + Guaifenesin | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Dextromethorphan Polistirex | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Diphenhydramine + Dextromethorphan + Levomenthol | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Doxepin (Oral) | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as antidepressants and lithium may potentiate the… | 7 sources — open the full entry |
| Doxepin (Topical) | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Duloxetine Hydrochloride | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Efavirenz | Major | Metabolism | Efavirenz can cause significant QT interval prolongation in patients with the CYP450 2B6 *6/*6 genotype due to reduced metabolic clearance of the drug stemming… | 6 sources — open the full entry |
| Escitalopram Oxalate | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs)… | 16 sources — open the full entry |
| Fentanyl Citrate | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Fluoxetine Hydrochloride | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs)… | 16 sources — open the full entry |
| Fluphenazine + Nortriptyline | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as antidepressants and lithium may potentiate the…2 documented mechanisms | 31 sources — open the full entry |
| Fluvoxamine Maleate | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs)… | 16 sources — open the full entry |
| Gatifloxacin | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Synergy · Unknown | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…2 documented mechanisms | 28 sources — open the full entry |
| Guaifenesin + Dextromethorphan + Menthol | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Haloperidol | Major | Synergy | Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 14 sources — open the full entry |
| Hydroxychloroquine Sulphate | Major | Synergy | Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong… | 22 sources — open the full entry |
| Iloperidone | Major | Synergy | Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 9 sources — open the full entry |
| Imipramine Hydrochloride | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as antidepressants and lithium may potentiate the… | 7 sources — open the full entry |
| Ivabradine | Major | Synergy | Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that prolong… | 10 sources — open the full entry |
| Ivosidenib | Major | Synergy | Ivosidenib can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive… | 6 sources — open the full entry |
| Lasmiditan Hemisuccinate | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Lefamulin Acetate | Major | Synergy | Lefamulin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result… | 6 sources — open the full entry |
| Levomilnacipran Hydrochloride | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Linezolid | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Lithium Carbonate | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as antidepressants and lithium may potentiate the… | 7 sources — open the full entry |
| Loteprednol Etabonate + Gatifloxacin | Major | Synergy · Unknown | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…2 documented mechanisms | 28 sources — open the full entry |
| Maprotiline Hydrochloride | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as antidepressants and lithium may potentiate the… | 7 sources — open the full entry |
| Mifepristone | Major | Synergy | Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may… | 10 sources — open the full entry |
| Mifepristone + Misoprostol | Major | Synergy · Unknown | Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may…2 documented mechanisms | 10 sources — open the full entry |
Conditions
Conditions in which Ondansetron needs care, as documented in this source.
Long QT Syndrome
MajorECG changes including QT interval prolongation have been observed in patients receiving ondansetron. Additionally, there have been some postmarketing reports of Torsade de Pointes cases. The use of ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.
2 sources
- "Product Information. Zofran (ondansetron)." GlaxoSmithKline (2001):
- "Product Information. Zuplenz (ondansetron)." Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc. (2010):
Liver Diseases
ModerateOndansetron is extensively metabolized by the liver. The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function. During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported. Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease. The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.
9 sources
- Finn AL "Toxicity and side effects of ondansetron." Semin Oncol 19 (1992): 53-60
- Blake JC, Palmer JL, Minton NA, Burroughs AK "The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment." Br J Clin Pharmacol 35 (1993): 441-3
- Colthup PV, Palmer JL "The determination in plasma and pharmacokinetics of ondansetron." Eur J Cancer Clin Oncol 25 (1989): s71-4
- Bryson JC "Clinical safety of ondansetron." Semin Oncol 19 (1992): 26-32
- "Product Information. Zofran (ondansetron)." GlaxoSmithKline (2001):
- Verrill M, Judson I "Jaundice with ondansetron." Lancet 344 (1994): 190-1
- Roila F, Delfavero A "Ondansetron clinical pharmacokinetics." Clin Pharmacokinet 29 (1995): 95-109
- Figg WE, Dukes GE, Pritchard JF, et al. "Ondansetron (OND) pharmacokinetics in chronic liver disease (LD)." Clin Pharmacol Ther 51 (1992): 171
Show all 9 sourcesShow fewer sources
- Figg WD, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, Songer SS, Powell R, Hak LJ "Pharmacokinetics of ondansetron in patients with hepatic insufficiency." J Clin Pharmacol 36 (1996): 206-15
Therapeutic duplication
Drug classes that overlap with Ondansetron, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
5ht3 receptor antagonists
The recommended maximum number of medicines in the '5HT3 receptor antagonists' category to be taken concurrently is usually one.Your list includes two medicines belonging to the '5HT3 receptor antagonists' category.
Example product in the source data (US market): Fosnetupitant/palonosetron
5ht3 receptor antagonists
The recommended maximum number of medicines in the '5HT3 receptor antagonists' category to be taken concurrently is usually one.Your list includes two medicines belonging to the '5HT3 receptor antagonists' category.
Example product in the source data (US market): Netupitant/palonosetron